Overview

Dose-ranging Study

Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
Dose ranging study
Phase:
Phase 2
Details
Lead Sponsor:
Neothetics, Inc
Treatments:
Fluticasone
Salmeterol Xinafoate
Xhance